Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
322 stopped studies mapped to Chronic Leukemia and descendants · 84% state a reason
Over the 322 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00801060 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR)… | Phase 2 | terminated | Dec 3, 2008 | Biogen | not stated | Not stated |
| NCT01625741 | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients…(HYDRIC) | Phase 2 | terminated | Jun 21, 2012 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Stopped by Principal Investigator decision | Investigator |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular… | Phase 2 | terminated | Aug 15, 2006 | National Cancer Institute (NCI) | Study terminated due to low accrual and the investigator left the NIH. | Investigator |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | Phase 2 | terminated | Dec 19, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00771602 | Alemtuzumab + Rituximab Consolidation in CLL | Phase 2 | terminated | Oct 13, 2008 | M.D. Anderson Cancer Center | Lack of accrual. | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01271283 | Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | Phase 2 | withdrawn | Jan 6, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study… | Phase 1 / Phase 2 | terminated | Jul 19, 2011 | University of Ulm | Insufficient recruitment | Enrollment / accrual |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic… | Phase 1 | terminated | Dec 24, 2004 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01463852 | A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation… | Early Phase 1 | terminated | Nov 2, 2011 | Dartmouth-Hitchcock Medical Center | Enrollment underperformance. | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Oct 8, 2004 | GlaxoSmithKline | Acquired asset | Other (stated, no rule matched) |
| NCT00845104 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell… | Phase 2 | withdrawn | Feb 18, 2009 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | No patients enrolled. | Enrollment / accrual |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | Phase 2 | terminated | Jun 8, 2009 | King's College Hospital NHS Trust | Recruitment issues | Enrollment / accrual |
| NCT00509249 | Aflibercept in Treating Patients With Myelodysplastic Syndromes | Phase 2 | terminated | Jul 31, 2007 | National Cancer Institute (NCI) | Early termination for discouraging results | Other (stated, no rule matched) |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01465230 | Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy… | Phase 2 | terminated | Nov 4, 2011 | Yale University | This study was unsuccessful in enrolling the target number of subjects during the funding period. | Enrollment / accrual |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | terminated | Feb 7, 2006 | National Cancer Institute (NCI) | NCI stopped supplying fenretinide in November of 2012. | Other (stated, no rule matched) |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | suspended | Apr 17, 2014 | Piramal Enterprises Limited | Sponsor decision not related to patient safety | Safety / toxicity |
| NCT01005979 | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of… | Phase 1 | terminated | Nov 2, 2009 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | Phase 1 / Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or… | Phase 2 | terminated | Jan 5, 2005 | Pharmacyclics LLC. | not stated | Not stated |
| NCT00183950 | Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic… | Phase 1 / Phase 2 | terminated | Sep 16, 2005 | University of Southern California | No funding | Funding |
| NCT00303966 | Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Phase 2 | terminated | Mar 17, 2006 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01426334 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia… | Phase 1 | terminated | Aug 31, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or… | Phase 1 / Phase 2 | terminated | Jul 11, 2007 | Gilead Sciences | Unacceptable safety profile | Safety / toxicity |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | Phase 1 | withdrawn | Dec 1, 2010 | Roswell Park Cancer Institute | lost sponsor support | Other (stated, no rule matched) |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | Phase 2 | terminated | May 12, 2009 | Marshall University | Original Principal Investigator left the institution. | Investigator |
| NCT00836043 | Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic… | — | terminated | Feb 4, 2009 | Genzyme, a Sanofi Company | Study terminated due to low enrollment. | Enrollment / accrual |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing… | Phase 2 | terminated | Dec 28, 2011 | Texas Oncology Cancer Center | Insufficient accruals | Enrollment / accrual |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic… | Phase 1 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated… | Phase 1 | terminated | Feb 11, 2008 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | terminated | Jul 28, 2009 | Case Comprehensive Cancer Center | No more eligible patients | Other (stated, no rule matched) |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | Phase 1 | withdrawn | Apr 1, 2009 | Bristol-Myers Squibb | Business Objectives Changed | Sponsor / business decision |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small… | Phase 1 | terminated | Sep 15, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098488 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients… | Phase 1 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101088 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00108108 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is… | Phase 1 | terminated | Apr 15, 2005 | Novartis Pharmaceuticals | Slow enrollment and minimal preliminary biological and clinical efficacy. | Efficacy / futility |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single… | Phase 2 | withdrawn | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 2, 2015source: clinicaltrials